Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kaplan-Meier Approach01:24

Kaplan-Meier Approach

111
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
111
Cancer Survival Analysis01:21

Cancer Survival Analysis

334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
Actuarial Approach01:20

Actuarial Approach

68
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
68
Cancer Vaccines01:30

Cancer Vaccines

347
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
347
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

162
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
162
Censoring Survival Data01:09

Censoring Survival Data

72
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
72

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A bounded hazard ratio Cox model for the effect of time to treatment on mortality.

Statistical methods in medical research·2026
Same author

Children Hospitalized With Pneumonia Who Complete Oral Antibiotic Treatment Without Complications.

Hospital pediatrics·2026
Same author

Clinician Perceptions of the Impact of Switching HPV Vaccine Initiation to 9-10 Years.

Pediatrics·2026
Same author

Intravenous line-related outcomes by antibiotic route for children hospitalized with pneumonia.

Journal of hospital medicine·2025
Same author

Increasing opportunities for community input in harm reduction program development using iterative engagement.

Harm reduction journal·2025
Same author

Engaging Latinx Youth in PhotoVoice to Inform Message Development to Improve COVID-19 Vaccine Uptake.

The Journal of adolescent health : official publication of the Society for Adolescent Medicine·2025

Related Experiment Video

Updated: Jun 14, 2025

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.4K

Approximate maximum likelihood estimation in cure models using aggregated data, with application to HPV vaccine

John D Rice1, Allison Kempe2

  • 1Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA.

Statistics in Medicine
|September 5, 2024
PubMed
Summary

This study introduces new statistical methods to analyze aggregated survival data for estimating childhood vaccination rates, even without individual patient data. These methods help public health officials target interventions more effectively to combat rising communicable diseases.

Keywords:
Chebyshev polynomialsapproximate likelihoodcure modelsdata privacysummary statisticsvaccine hesitancy

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K
Development and Validation of a Quantitative PCR Method for Equid Herpesvirus-2 Diagnostics in Respiratory Fluids
09:57

Development and Validation of a Quantitative PCR Method for Equid Herpesvirus-2 Diagnostics in Respiratory Fluids

Published on: March 17, 2016

28.3K

Related Experiment Videos

Last Updated: Jun 14, 2025

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.4K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.7K
Development and Validation of a Quantitative PCR Method for Equid Herpesvirus-2 Diagnostics in Respiratory Fluids
09:57

Development and Validation of a Quantitative PCR Method for Equid Herpesvirus-2 Diagnostics in Respiratory Fluids

Published on: March 17, 2016

28.3K

Area of Science:

  • Biostatistics
  • Public Health
  • Epidemiology

Background:

  • Increasing rates of vaccine-preventable communicable diseases necessitate improved childhood immunization strategies.
  • Estimating 'never-vaccinator' proportions is crucial for targeted public health interventions.
  • Privacy concerns often restrict access to individual patient data (IPD), hindering traditional survival analyses.

Purpose of the Study:

  • To develop and validate statistical methods for analyzing aggregated survival data.
  • To accommodate a 'cured fraction' within survival models using only summary statistics.
  • To address the challenge of analyzing vaccination uptake data when IPD is unavailable.

Main Methods:

  • Proposed a novel statistical methodology for the analysis of aggregated survival data.
  • Utilized a polynomial approximation of the mixture cure model log-likelihood function.
  • Validated the method through simulation studies and application to a real-world human papillomavirus (HPV) vaccination dataset.

Main Results:

  • The proposed statistical methodology effectively analyzes aggregated survival data.
  • The method successfully accommodates a cured fraction, providing estimates of 'never-vaccinators'.
  • Demonstrated applicability to real-world vaccination uptake studies, such as HPV vaccination.

Conclusions:

  • The developed methods offer a viable approach for analyzing complex survival models with aggregated data.
  • These techniques can overcome data privacy barriers and other concerns limiting IPD access.
  • The methodology can be generalized for various public health research scenarios requiring survival analysis without individual-level data.